# EDGAR Filing Document

**Accession Number:** 0001829252
**File Stem:** 0001735276-23-000033
**Filing Date:** 2023-3
**Character Count:** 7273
**Document Hash:** 24f7595feb33789caeff0c17f74a6907
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001735276-23-000033.hdr.sgml**: 20230307

**ACCESSION NUMBER**: 0001735276-23-000033

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230303

**FILED AS OF DATE**: 20230307

**DATE AS OF CHANGE**: 20230307

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Garg Pushkal
- **CENTRAL INDEX KEY:** 0001829252

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36407
- **FILM NUMBER:** 23712652

**MAIL ADDRESS:**
- **STREET 1:** C/O SQZ BIOTECHNOLOGIES COMPANY
- **STREET 2:** 200 ARSENAL YARDS BOULEVARD, SUITE 210
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALNYLAM PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001178670
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 770602661
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 675 WEST KENDALL STREET
- **STREET 2:** HENRI A. TERMEER SQUARE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** (617) 551-8200

**MAIL ADDRESS:**
- **STREET 1:** 675 WEST KENDALL STREET
- **STREET 2:** HENRI A. TERMEER SQUARE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALNYLAM PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20020724

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Garg Pushkal<br><sub>(Last) (First) (Middle)</sub><br>675 WEST KENDALL STREET<br>HENRI A. TERMEER SQUARE<br><sub>(Street)</sub><br>CAMBRIDGE, MA 02142<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-03 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_CMO & EVP Dev & Med Affairs_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>ALNYLAM PHARMACEUTICALS, INC. [ ALNY ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2023-03-03 |  | M<sup>(1)</sup> |  | 2500 | A | $96.45 | 19917 | D |  |
| Common Stock | 2023-03-03 |  | M<sup>(1)</sup> |  | 2500 | A | $96.45 | 22417 | D |  |
| Common Stock | 2023-03-03 |  | S<sup>(1)</sup> |  | 18072 | D | $200.0 | 4345 | D |  |
| Common Stock |  |  |  |  |  |  |  | 431 | I | by Managed Account<sup>(2)</sup> |
| Common Stock |  |  |  |  |  |  |  | 250 | I | by Trust<sup>(3)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Performance Stock Option 2014 (right to buy) | $96.45 | 2023-03-03 |  | M<sup>(1)</sup> |  |  | 2500 | 2018-08-11 | 2024-12-17 | Common Stock | 2500 | $0.0 | 0 | D |  |
| Stock Option  (right to buy) | $96.45 | 2023-03-03 |  | M<sup>(1)</sup> |  |  | 2500 | <sup>(4)</sup> | 2024-12-17 | Common Stock | 2500 | $0.0 | 0 | D |  |

---

### Footnotes:

(1) All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022.

(2) Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.

(3) Represents shares held in trust, of which the reporting persons spouse is co-trustee. The reporting person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

(4) The stock option vested as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares at the end of each successive three month period thereafter until the fourth anniversary of the grant date, and were fully vested on December 17, 2018.

**Signature:** By: /s/ Andrew Mayer, Attorney-in-Fact For: Pushkal Garg  
**Date:** 2023-03-07

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**